/
/
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
This content is Free Access.
Chapitres
- 00:05Titre
- 01:06Bone Marrow Aspiration and Smear Preparation
- 03:16Flow Cytometry Setup
- 05:53Cell Staining for Flow Cytometry
- 07:45Results: Representative Leukemia-associated Immunophenotype (LAIP) Gating
- 08:46Conclusion
Detection of minimal or measurable residual disease (MRD) is an important prognostic biomarker for refining risk assessment and predicting relapse in acute myeloid leukemia (AML). These comprehensive guidelines and recommendations with best practices for consistent and accurate identification and detection of MRD, may aid in making effective AML treatment decisions.
